Emery-Dreifuss muscular dystrophy, nuclear cell signaling and chromatin remodeling

Nadir M. Maraldi, Stefano Squarzoni, Patrizia Sabatelli, Giovanna Lattanzi, Andrea Ognibene, Francesco A. Manzoli

Research output: Contribution to journalArticle

Abstract

Emery-Dreifuss muscular dystrophy (EDMD), a rare form of myopathy, is caused by mutations in either STA gene that encodes the nuclear membrane-associated protein emerin (X-EDMD), or LMNA gene that encodes the nuclear lamin A/C (AD-EDMD). Whilst other muscular dystrophies are due to the loss or altered expression of molecules located at the plasma membrane/cytoskeleton/extracellular matrix system, emerin and lamin A/C are localized at the nuclear envelope/nuclear matrix interface. Other apparently unrelated human diseases, such as a form of dilated cardiomyopathy (CMD1A) and Dunnigan-type familial partial lipodystrophy (FPLD), are also due to naturally occurring mutations within LMNA gene and have been thus defined "nuclear envelopathies". Different hypotheses have been proposed on EDMD pathogenesis, including the regulation of cell-type-specific gene expression by chromatin-nuclear envelope interactions. The control of gene expression through the release of template restriction depends on the chromatin organization that, in turn, is modulated by interactions with the nuclear envelope. Moreover, the nucleus is not only the final target of signals but, in response to them, activates an autonomous signaling pathway based on inositol lipids that are phosphorylated and hydrolyzed at specific intranuclear sites. The nuclear inositide signaling system is involved in key functions, such as the control of DNA synthesis and of transcript splicing, as well as in heterochromatin decondensation that represents a prerequisite of gene transcription. Chromatin remodeling complexes (CRC), that contain actin and actin-binding proteins, are modulated by inositol lipids at the nuclear matrix level. Therefore, it is conceivable that the altered expression of emerin and lamin A/C that interacts with nuclear actin may affect the chromatin arrangement and gene expression. This can result in modified patterns of development of some cell lineages of common mesenchymal origin and prevent correct mechanisms of differentiation of the muscle satellite cells in the adult.

Original languageEnglish
Pages (from-to)1-18
Number of pages18
JournalAdvances in Enzyme Regulation
Volume42
DOIs
Publication statusPublished - 2002

Fingerprint

Emery-Dreifuss Muscular Dystrophy
Cell signaling
Chromatin Assembly and Disassembly
Nuclear Envelope
Lamin Type A
Chromatin
Genes
Gene expression
Nuclear Matrix
Inositol
Gene Expression
Actins
Familial Partial Lipodystrophy
Lipids
Microfilament Proteins
Mutation
Heterochromatin
Muscular Dystrophies
Dilated Cardiomyopathy
Cell Lineage

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Biology

Cite this

Emery-Dreifuss muscular dystrophy, nuclear cell signaling and chromatin remodeling. / Maraldi, Nadir M.; Squarzoni, Stefano; Sabatelli, Patrizia; Lattanzi, Giovanna; Ognibene, Andrea; Manzoli, Francesco A.

In: Advances in Enzyme Regulation, Vol. 42, 2002, p. 1-18.

Research output: Contribution to journalArticle

@article{e5762ca632bf47978ab8ec1032018f35,
title = "Emery-Dreifuss muscular dystrophy, nuclear cell signaling and chromatin remodeling",
abstract = "Emery-Dreifuss muscular dystrophy (EDMD), a rare form of myopathy, is caused by mutations in either STA gene that encodes the nuclear membrane-associated protein emerin (X-EDMD), or LMNA gene that encodes the nuclear lamin A/C (AD-EDMD). Whilst other muscular dystrophies are due to the loss or altered expression of molecules located at the plasma membrane/cytoskeleton/extracellular matrix system, emerin and lamin A/C are localized at the nuclear envelope/nuclear matrix interface. Other apparently unrelated human diseases, such as a form of dilated cardiomyopathy (CMD1A) and Dunnigan-type familial partial lipodystrophy (FPLD), are also due to naturally occurring mutations within LMNA gene and have been thus defined {"}nuclear envelopathies{"}. Different hypotheses have been proposed on EDMD pathogenesis, including the regulation of cell-type-specific gene expression by chromatin-nuclear envelope interactions. The control of gene expression through the release of template restriction depends on the chromatin organization that, in turn, is modulated by interactions with the nuclear envelope. Moreover, the nucleus is not only the final target of signals but, in response to them, activates an autonomous signaling pathway based on inositol lipids that are phosphorylated and hydrolyzed at specific intranuclear sites. The nuclear inositide signaling system is involved in key functions, such as the control of DNA synthesis and of transcript splicing, as well as in heterochromatin decondensation that represents a prerequisite of gene transcription. Chromatin remodeling complexes (CRC), that contain actin and actin-binding proteins, are modulated by inositol lipids at the nuclear matrix level. Therefore, it is conceivable that the altered expression of emerin and lamin A/C that interacts with nuclear actin may affect the chromatin arrangement and gene expression. This can result in modified patterns of development of some cell lineages of common mesenchymal origin and prevent correct mechanisms of differentiation of the muscle satellite cells in the adult.",
author = "Maraldi, {Nadir M.} and Stefano Squarzoni and Patrizia Sabatelli and Giovanna Lattanzi and Andrea Ognibene and Manzoli, {Francesco A.}",
year = "2002",
doi = "10.1016/S0065-2571(01)00022-X",
language = "English",
volume = "42",
pages = "1--18",
journal = "Advances in Enzyme Regulation",
issn = "0065-2571",
publisher = "Elsevier BV",

}

TY - JOUR

T1 - Emery-Dreifuss muscular dystrophy, nuclear cell signaling and chromatin remodeling

AU - Maraldi, Nadir M.

AU - Squarzoni, Stefano

AU - Sabatelli, Patrizia

AU - Lattanzi, Giovanna

AU - Ognibene, Andrea

AU - Manzoli, Francesco A.

PY - 2002

Y1 - 2002

N2 - Emery-Dreifuss muscular dystrophy (EDMD), a rare form of myopathy, is caused by mutations in either STA gene that encodes the nuclear membrane-associated protein emerin (X-EDMD), or LMNA gene that encodes the nuclear lamin A/C (AD-EDMD). Whilst other muscular dystrophies are due to the loss or altered expression of molecules located at the plasma membrane/cytoskeleton/extracellular matrix system, emerin and lamin A/C are localized at the nuclear envelope/nuclear matrix interface. Other apparently unrelated human diseases, such as a form of dilated cardiomyopathy (CMD1A) and Dunnigan-type familial partial lipodystrophy (FPLD), are also due to naturally occurring mutations within LMNA gene and have been thus defined "nuclear envelopathies". Different hypotheses have been proposed on EDMD pathogenesis, including the regulation of cell-type-specific gene expression by chromatin-nuclear envelope interactions. The control of gene expression through the release of template restriction depends on the chromatin organization that, in turn, is modulated by interactions with the nuclear envelope. Moreover, the nucleus is not only the final target of signals but, in response to them, activates an autonomous signaling pathway based on inositol lipids that are phosphorylated and hydrolyzed at specific intranuclear sites. The nuclear inositide signaling system is involved in key functions, such as the control of DNA synthesis and of transcript splicing, as well as in heterochromatin decondensation that represents a prerequisite of gene transcription. Chromatin remodeling complexes (CRC), that contain actin and actin-binding proteins, are modulated by inositol lipids at the nuclear matrix level. Therefore, it is conceivable that the altered expression of emerin and lamin A/C that interacts with nuclear actin may affect the chromatin arrangement and gene expression. This can result in modified patterns of development of some cell lineages of common mesenchymal origin and prevent correct mechanisms of differentiation of the muscle satellite cells in the adult.

AB - Emery-Dreifuss muscular dystrophy (EDMD), a rare form of myopathy, is caused by mutations in either STA gene that encodes the nuclear membrane-associated protein emerin (X-EDMD), or LMNA gene that encodes the nuclear lamin A/C (AD-EDMD). Whilst other muscular dystrophies are due to the loss or altered expression of molecules located at the plasma membrane/cytoskeleton/extracellular matrix system, emerin and lamin A/C are localized at the nuclear envelope/nuclear matrix interface. Other apparently unrelated human diseases, such as a form of dilated cardiomyopathy (CMD1A) and Dunnigan-type familial partial lipodystrophy (FPLD), are also due to naturally occurring mutations within LMNA gene and have been thus defined "nuclear envelopathies". Different hypotheses have been proposed on EDMD pathogenesis, including the regulation of cell-type-specific gene expression by chromatin-nuclear envelope interactions. The control of gene expression through the release of template restriction depends on the chromatin organization that, in turn, is modulated by interactions with the nuclear envelope. Moreover, the nucleus is not only the final target of signals but, in response to them, activates an autonomous signaling pathway based on inositol lipids that are phosphorylated and hydrolyzed at specific intranuclear sites. The nuclear inositide signaling system is involved in key functions, such as the control of DNA synthesis and of transcript splicing, as well as in heterochromatin decondensation that represents a prerequisite of gene transcription. Chromatin remodeling complexes (CRC), that contain actin and actin-binding proteins, are modulated by inositol lipids at the nuclear matrix level. Therefore, it is conceivable that the altered expression of emerin and lamin A/C that interacts with nuclear actin may affect the chromatin arrangement and gene expression. This can result in modified patterns of development of some cell lineages of common mesenchymal origin and prevent correct mechanisms of differentiation of the muscle satellite cells in the adult.

UR - http://www.scopus.com/inward/record.url?scp=0036375918&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036375918&partnerID=8YFLogxK

U2 - 10.1016/S0065-2571(01)00022-X

DO - 10.1016/S0065-2571(01)00022-X

M3 - Article

C2 - 12123703

AN - SCOPUS:0036375918

VL - 42

SP - 1

EP - 18

JO - Advances in Enzyme Regulation

JF - Advances in Enzyme Regulation

SN - 0065-2571

ER -